Search Results

Empirical Studies Assessing the Perceptions and Knowledge of Medicine in Mongolia: A Nationwide Population-Based Study.

• Authors : Lkhagvasuren, Dulmaa¹; Bayarbat, Uranbileg¹; Khongorzul, Ganbat¹

• Source: Indonesian Journal of Pharmacy / Majalah Farmasi Indonesia. Jan-Mar2024, Vol. 35 Issue 1, p162-170. 9p.

Record details

The usage and costs of national drug price-negotiated anticancer medicines in a first-tier city in Northeast China: a study based on health insurance data.

• Authors : Li, Bao-Xin¹ (AUTHOR); Wang, Ya-Qun¹ (AUTHOR); Yi, Yuan-Yuan² (AUTHOR)

Subjects: *HEALTH insurance; *BUSINESS negotiation; *DRUG accessibilityCHINA

• Source: BMC Public Health. 5/14/2024, Vol. 24, p1-12. 12p.

Record details

DECREASING PRESCRIPTION DRUG PRICES: CAN EFFECTIVE POLICY INCENTIVE COOPERATION BETWEEN PREVIOUSLY ANTITHETIC SECTORS?

• Authors : Brown, Benjamin E.

Subjects: DRUG prices; HEALTH insurance; MEDICAL care

• Source: Indiana Health Law Review. 2017, Vol. 14 Issue 1, p162-192. 31p.

Record details

ID 169. The Impact of Rising Drug Prices in Egypt.

• Authors : Abdeldaiem, Mahmoud Said Ibrahim¹ ; Fathalla, Nour Allah Hassan²; El-Sayed, Nouran Ehab Hassan²

• Source: Journal of Pharmacy & Bioallied Sciences. 2020 Supplement, Vol. 12, p909-909. 1/3p.

Record details

The annual economic burden incurred by heart failure patients in Vietnam: a retrospective analysis.

• Authors : Dao, Tien Duc¹ (AUTHOR); Tran, Hien Thi Bich² (AUTHOR); Vu, Quynh Van² (AUTHOR)

• Source: Journal of Pharmaceutical Policy & Practice. Dec2024, Vol. 17 Issue 1, p1-24. 24p.

Record details

Discussion on stakeholders behind unfair drug pricing: A scoping review.

• Authors : Asad, Arif Ibne¹ ; Sabary, Gul Shah²

Subjects: *DRUG prices; *HEALTH insurance; *PRICE increases

• Source: Journal of Competitiveness. Sep2023, Vol. 15 Issue 3, p3-18. 16p.

Record details

Price trends of reimbursed oncological drugs in Switzerland in 2005–2019: A descriptive analysis.

• Authors : Rachamin, Yael¹ (AUTHOR); Ackermann, Christoph Jakob² (AUTHOR); Senn, Oliver¹ (AUTHOR)

Subjects: *PROTEIN kinase inhibitors; *MONOCLONAL antibodies; *HEMATOLOGIC malignanciesSWITZERLAND

• Source: PLoS ONE. 11/15/2021, Vol. 16 Issue 11, p1-12. 12p.

Record details

Budget impact analysis of high-priced orphan medicinal products intended for the treatment of rare diseases in China: evidence from a densely populated metropolis of Chengdu.

• Authors : Zhang, Xiaoxing^1,2 (AUTHOR); Zhou, Tingting³ (AUTHOR); Zhou, Jing^1,2 (AUTHOR)

• Source: BMC Health Services Research. 9/27/2024, Vol. 24 Issue 1, p1-11. 11p.

Record details

DRG 付费制度下基于 O/E 模型优化 ET25 病组 用药管理的实践与探索.

• Authors : 伍渊麟; 刘 耀; 甘岚澜

Subjects: MEDICAL care costs; CHRONIC obstructive pulmonary disease; ECONOMIC aspects of diseases

• Source: Evaluation & Analysis of Drug-Use in Hospitals of China / Zhongguo Yiyuan Yongyao Pingjia yu Fenxi; 2024, Vol. 24 Issue 12, p1518-1521, 4p

Record details

PSI-MEREC-MACONT HİBRİT MODELİ İLE TÜRKİYE SAĞLIK SİGORTA BRANŞININ YILLARA GÖRE PERFORMANS SIRALAMASI.

• Authors : AYDIN ÜNAL, Esra

Subjects: INSURANCE companies; HEALTH insurance; HOSPITAL costs

• Source: Karamanoglu Mehmetbey University Journal of Social & Economic Research / Karamanoğlu Mehmetbey Üniversitesi Sosyal ve Ekonomi̇k Araştırmalar Dergi̇si; Dec2024, Vol. 26 Issue 47, p793-813, 21p

Record details